Natural gene therapy for intractable skin disease discovered

sciencedaily | April 01, 2019

In general, there is no fundamental treatment method capable of curing diseases caused by gene abnormality because it is difficult to remove certain genetic mutations from all affected cells. Loricrin keratoderma (LK) is one such disease; caused by loricrin mutations, it is characterized by dry, thickened, scaly skin from birth. Only symptomatic treatments are available to alleviate the conditions, which cause difficulties in patients' daily lives. Thus far, doctors have not known how to treat the ailment.

Spotlight

Conosco provides outsourced IT based on solid support and strategic thinking for London-based companies including Cadogan Estates, Dennis Publishing, Moonpig and Issey Miyake.

Spotlight

Conosco provides outsourced IT based on solid support and strategic thinking for London-based companies including Cadogan Estates, Dennis Publishing, Moonpig and Issey Miyake.

Related News

MEDICAL

Recipharm and Moderna Finalize Agreement to Support Formulation and Fill-Finish a part of the Moderna COVID-19 Vaccine Supply Outside of the U.S.

Recipharm | January 04, 2021

Moderna, Inc. (NASDAQ:MRNA), biotechnology organization spearheading courier RNA (mRNA) therapeutics and vaccines, and Recipharm (STO: RECI-B), a main contract development and manufacturing organization (CDMO), today reported that they have agreed to help detailing and fill-finish a part of the Moderna COVID-19 Vaccine supply outside of the U.S. The action will be acted in Recipharm's medication item producing office located in France. Subject to regulatory approval of the immunization in important nations outside of the U.S., it is anticipated that supply will commence in early 2021. “We are making important progress in the development of the Moderna COVID-19 Vaccine and we are pleased to be entering into this collaboration with Recipharm,” said Nicolas Chornet, Senior Vice President, International Manufacturing of Moderna. “We look forward to their support in the delivery of our vaccine to market.”

Read More

Emerging Biotechnology Company Biocytogen Raised 142 Million Dollars (USD) in Support of Project Integrum

Biocytogen | September 25, 2020

In August, Beijing Biocytogen Biotechnology Co., Ltd. ("Biocytogen") announced acquisition of Eucure Biopharma, which established Biocytogen as a clinical stage company. Now, Biocytogen is pleased to announce completion of series D1 Funding, successfully raising 142 million dollars (USD) meant to further secure the implementation of Project Integrum.Project Integrum is a humanitarian effort to discover, develop, and bring to market novel therapeutic antibody candidates against all notoriously difficult druggable targets. Taking full advantage of Biocytogen's integrated technology platforms for antibody discovery, Project Integrum will launch pre-clinical efforts into over 1,000 human diseases currently affecting countless lives.Meticulous screening of antibody candidates both in vivo and in vitro improves clinical translatability dramatically. At the core of Biocytogen lie the humanized antibody RenMab Mouse and a hoard of proprietary advanced gene targeting strategies, which have been fully optimized and integrated with the most advanced, complementary technologies in the express goal of discovering therapeutic, clinically-relevant antibodies.

Read More

CELL AND GENE THERAPY

WuXi ATU Announces Launch of TESSA™ Technology to Improve Scalability and Accessibility of Cell and Gene Therapies

WuXi AppTec | March 08, 2022

WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced the launch of Tetracycline-Enabled Self-Silencing Adenovirus (TESSA™). This technology is a state-of-the-art novel process for transfection-free, scalable manufacture of adeno-associated virus (AAV) at Good Manufacturing Practice (GMP) grade. Developed by OXGENE in the United Kingdom, a WuXi Advanced Therapies company, TESSA™ will expedite AAV manufacturing and significantly reduce the cost for manufacturing cell and gene therapies, enabling global customers to deliver more accessible ground-breaking therapeutics to patients as quickly as possible. AAV vector is a popular tool for the delivery of gene therapies in diseases such as haemophilia and Alzheimer's. Efficient processes for manufacturing AAV on a large scale are critical to meeting increasing industry demands. TESSA™ vectors can meet the scalability challenges of AAV production, which has significant implications for expanding patient access to these novel therapeutics. The new data published in Nature Communications supports the benefits of this technology. It highlights that in the same manufacturing volume, TESSA™ vectors produced 10 times more AAV than plasmid-based manufacture, producing enough material to treat ten times the number of patients. The TESSA™ system is a game changer for the manufacture of AAV and the advancement of cell and gene therapies to benefit patients. By improving scalability, reducing process complexity and lowering the costs of gene therapy manufacture, TESSA™ will better enable our global partners to develop and deliver life-saving gene therapies faster to more patients in need." Dr. Ryan Cawood, Chief Scientific Officer of WuXi ATU. As a Contract Testing Development and Manufacturing Organization (CTDMO) with operations globally, WuXi ATU's unique business model integrates powerful testing capabilities with its advanced therapies' process development and manufacturing platforms, such as TESSA™ technology for AAV manufacturing and Lenti stable solutions for lentiviral manufacturing. This allows all assay development, biosafety, viral clearance and product release testing to be completed in-house, shortening customers' timelines for the approval of advanced therapies. About WuXi Advanced Therapies (WuXi ATU) As the advanced therapies business unit of WuXi AppTec, WuXi Advanced Therapies is a Contract Testing, Development and Manufacturing Organization (CTDMO) that offers integrated platforms to transform the discovery, development, testing, manufacturing, and commercialization of cell and gene therapies. Our services and solutions accelerate time to market and support customer programs around the world.

Read More